The first primary endpoint of OPT Retreatment evaluated the maintenance of clinical response in patients who remained on tofacitinib after ...
No new safety signals for tofacitinib were observed in the OPT Pivotal #1 or OPT Pivotal #2 studies. Detailed analyses ...
Pfizer Inc. announced today detailed results from OPT Compare (A3921080), a Phase 3 study of tofacitinib, the first in a ...
777Funds , a Nigeria-based decentralized finance (DeFi) startup, today reported continued product and market progress as it nears mainnet deployment...
Read moreDetails
PressCenter.com is state-of-the-art Press Release Distribution Platform. PressCenter.com send and track your Press Release using our industry-leading global Media Contacts Database of a million contacts. Your Press Release will reach business news editors and journalists, in targeted sectors and territories or worldwide.
